Resmetirom is an experimental drug for the treatment of non-alcoholic steatohepatitis (NASH.
It is a selective agonist of thyroid hormone receptor beta, which increases hepatic fat metabolism, and reduces lipotoxicity.
Thyroid hormone receptor beta (THR – beta), agonist reverses steatosis by improving hepatic conversion of T4 to T3, and enhancing mitochondrial function.
THR beta Resmetirom can activate, the major thyroid hormone receptor isoform in the liver, kidneys, pituitary, and brain while avoiding thyroid hormone receptor, alpha related side effects in the heart and bones.